Detalhe da pesquisa
1.
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
N Engl J Med
; 387(8): 704-714, 2022 08 25.
Artigo
Inglês
| MEDLINE | ID: mdl-36001711
2.
A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.
Mult Scler
; 27(3): 420-429, 2021 03.
Artigo
Inglês
| MEDLINE | ID: mdl-32351164